April 12, 2018 / 7:30 AM / in 2 months

BRIEF-Destiny Pharma Says On Track To Deliver Phase 2B Headline Data In H2 2019 For Xf-73

* WELL FUNDED AND ON TRACK TO DELIVER PHASE 2B HEADLINE DATA IN H2 2019 FOR LEAD ASSET, XF-73, A NOVEL ANTI-MICROBIAL

* FY LOSS BEFORE INCOME TAX 3.2 MILLION POUNDS VERSUS 1.4 MILLION POUNDS Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below